140 related articles for article (PubMed ID: 37844755)
41. Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition.
Kim HJ; Lee J; Chung MY; Hong S; Park JH; Lee SH; Park SW; Choi HK; Hwang JT
Pharmacol Res; 2020 Nov; 161():105205. PubMed ID: 32998069
[TBL] [Abstract][Full Text] [Related]
42. Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey.
Jensen KK; Tadin-Strapps M; Wang SP; Hubert J; Kan Y; Ma Y; McLaren DG; Previs SF; Herath KB; Mahsut A; Liaw A; Wang S; Stout SJ; Keohan C; Forrest G; Coelho D; Yendluri S; Williams S; Koser M; Bartz S; Akinsanya KO; Pinto S
J Lipid Res; 2016 Dec; 57(12):2150-2162. PubMed ID: 27707816
[TBL] [Abstract][Full Text] [Related]
43. Turnover Rates of the Low-Density Lipoprotein Receptor and PCSK9: Added Dimension to the Cholesterol Homeostasis Model.
Dandan M; Han J; Mann S; Kim R; Mohammed H; Nyangau E; Hellerstein M
Arterioscler Thromb Vasc Biol; 2021 Dec; 41(12):2866-2876. PubMed ID: 34615375
[TBL] [Abstract][Full Text] [Related]
44. Naringin Activates AMPK Resulting in Altered Expression of SREBPs, PCSK9, and LDLR To Reduce Body Weight in Obese C57BL/6J Mice.
Sui GG; Xiao HB; Lu XY; Sun ZL
J Agric Food Chem; 2018 Aug; 66(34):8983-8990. PubMed ID: 30092639
[TBL] [Abstract][Full Text] [Related]
45. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
46. Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats.
Su ZL; Hang PZ; Hu J; Zheng YY; Sun HQ; Guo J; Liu KY; Du ZM
Acta Pharmacol Sin; 2020 Aug; 41(8):1085-1092. PubMed ID: 32203084
[TBL] [Abstract][Full Text] [Related]
47. Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.
Shrestha P; Adepu S; Vivès RR; Masri RE; Klooster A; Kaptein F; Dam W; Bakker SJL; van Goor H; van de Sluis B; van den Born J
J Am Soc Nephrol; 2021 Jun; 32(6):1371-1388. PubMed ID: 33758009
[TBL] [Abstract][Full Text] [Related]
48. Pterostilbene Increases LDL Metabolism in HL-1 Cardiomyocytes by Modulating the PCSK9/HNF1α/SREBP2/LDLR Signaling Cascade, Upregulating Epigenetic hsa-miR-335 and hsa-miR-6825, and LDL Receptor Expression.
Lin YK; Yeh CT; Kuo KT; Yadav VK; Fong IH; Kounis NG; Hu P; Hung MY
Antioxidants (Basel); 2021 Aug; 10(8):. PubMed ID: 34439528
[TBL] [Abstract][Full Text] [Related]
49. PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients.
Huang J; Xiao J; Peng Z; Shao P; Sun M; Long Y; Wang X; Shen M; Kang D; Yang Y; Peng X; Wang W; Xie P; Shao T; Zhao J; Wu R
Psychopharmacology (Berl); 2022 Jan; 239(1):83-91. PubMed ID: 35029705
[TBL] [Abstract][Full Text] [Related]
50. [Lipid-lowering drugs and PCSK9].
Millán Núñez-Cortés J; Mostaza Prieto JM
Clin Investig Arterioscler; 2016 May; 28 Suppl 2():9-13. PubMed ID: 27888906
[TBL] [Abstract][Full Text] [Related]
51. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Shrestha P; van de Sluis B; Dullaart RPF; van den Born J
Cell Signal; 2019 Mar; 55():53-64. PubMed ID: 30550765
[TBL] [Abstract][Full Text] [Related]
52. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
Maxwell KN; Breslow JL
Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
[TBL] [Abstract][Full Text] [Related]
53. Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia.
Ma KL; Ruan XZ; Powis SH; Chen Y; Moorhead JF; Varghese Z
Transplantation; 2007 Oct; 84(8):1029-36. PubMed ID: 17989609
[TBL] [Abstract][Full Text] [Related]
54. Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-3-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas.
Mbikay M; Mayne J; Sirois F; Fedoryak O; Raymond A; Noad J; Chrétien M
Mol Nutr Food Res; 2018 May; 62(9):e1700729. PubMed ID: 29396908
[TBL] [Abstract][Full Text] [Related]
55. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
56. An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.
Ly K; Essalmani R; Desjardins R; Seidah NG; Day R
J Biol Chem; 2016 Nov; 291(47):24676-24687. PubMed ID: 27758865
[TBL] [Abstract][Full Text] [Related]
57. In vitro selection generates RNA aptamer that antagonizes PCSK9-LDLR interaction and recovers cellular LDL uptake.
Ando T; Yamamoto M; Yokoyama T; Horiuchi D; Kawakami T
J Biosci Bioeng; 2021 Mar; 131(3):326-332. PubMed ID: 33177004
[TBL] [Abstract][Full Text] [Related]
58. Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms.
Katsuki S; K Jha P; Lupieri A; Nakano T; Passos LSA; Rogers MA; Becker-Greene D; Le TD; Decano JL; Ho Lee L; Guimaraes GC; Abdelhamid I; Halu A; Muscoloni A; V Cannistraci C; Higashi H; Zhang H; Vromman A; Libby P; Keith Ozaki C; Sharma A; Singh SA; Aikawa E; Aikawa M
Circ Res; 2022 Nov; 131(11):873-889. PubMed ID: 36263780
[TBL] [Abstract][Full Text] [Related]
59. Novel oral nano-hepatic targeted anti-PCSK9 in hypercholesterolemia.
Salaheldin TA; Godugu K; Bharali DJ; Fujioka K; Elshourbagy N; Mousa SA
Nanomedicine; 2022 Feb; 40():102480. PubMed ID: 34748962
[TBL] [Abstract][Full Text] [Related]
60. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
Pedro-Botet J; Badimón L
Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
